ArriVent Biopharma
3 employees
Biotech
Public · $465.0M
Open positions (2)
Company details
Team Size3
IndustryBiotech
Funding
Total raised
$465.0M
Last stage
Public
Investors
OrbiMed
Total raised
$465.0M
Last stage
Public
Investors
Bing Yao
Accomplished executive and scientist with 20+ years in biopharma. Previously Chairman & CEO of Viela Bio (acquired by Horizon Therapeutics for $3.1B in 2021), and prior roles at MedImmune and AstraZeneca.
Robin LaChapelle
Experienced executive in strategic planning, HR, and capital raising. Previously Founder and Executive Director at RLT Consulting and VP of Human Resources at MedImmune/AstraZeneca North America.
Stuart Lutzker
Listed as President and Co-founder at ArriVent Biopharma.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.